AU2021107213A4 - Use of sphondin as an effective component in preparing medicine for treating hepatitis b - Google Patents

Use of sphondin as an effective component in preparing medicine for treating hepatitis b Download PDF

Info

Publication number
AU2021107213A4
AU2021107213A4 AU2021107213A AU2021107213A AU2021107213A4 AU 2021107213 A4 AU2021107213 A4 AU 2021107213A4 AU 2021107213 A AU2021107213 A AU 2021107213A AU 2021107213 A AU2021107213 A AU 2021107213A AU 2021107213 A4 AU2021107213 A4 AU 2021107213A4
Authority
AU
Australia
Prior art keywords
hbv
treatment
hepatitis
sphondin
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021107213A
Other languages
English (en)
Inventor
Juan Chen
Shengtao Cheng
Ailong HUANG
Fang REN
Jihua Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Medical University
Original Assignee
Chongqing Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Medical University filed Critical Chongqing Medical University
Application granted granted Critical
Publication of AU2021107213A4 publication Critical patent/AU2021107213A4/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021107213A 2021-05-11 2021-08-25 Use of sphondin as an effective component in preparing medicine for treating hepatitis b Active AU2021107213A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021105149667 2021-05-11
CN202110514966.7A CN113069445A (zh) 2021-05-11 2021-05-11 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途

Publications (1)

Publication Number Publication Date
AU2021107213A4 true AU2021107213A4 (en) 2021-12-09

Family

ID=76616475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021107213A Active AU2021107213A4 (en) 2021-05-11 2021-08-25 Use of sphondin as an effective component in preparing medicine for treating hepatitis b

Country Status (3)

Country Link
CN (1) CN113069445A (zh)
AU (1) AU2021107213A4 (zh)
WO (1) WO2022237007A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069445A (zh) * 2021-05-11 2021-07-06 重庆医科大学 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113304165B (zh) * 2021-07-15 2022-07-22 重庆医科大学 单体化合物Ciliatoside A在制备乙型肝炎治疗药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939167A (en) * 1988-07-22 1990-07-03 Jean Jacques Goupil Use of 5-methoxypsoralen and other furocoumarins as jet lag suppressants
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6242188B1 (en) * 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
US20090312406A1 (en) * 2008-06-12 2009-12-17 Hsing-Pang Hsieh Coumarin compounds and their use for treating viral infection
US20110268722A1 (en) * 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
CN101904839B (zh) * 2010-08-06 2012-06-20 中国人民解放军第二军医大学 欧芹素乙在制备防治肝炎或肝损伤药物中的应用
CN103191105B (zh) * 2013-03-18 2015-08-19 中山大学 一类呋喃香豆素类化合物在制备抗乙型肝炎病毒(hbv)药物中的应用
CN105616463A (zh) * 2014-11-10 2016-06-01 南京浩鼎生物科技有限公司 一种抑制乙肝病毒用的无副作用调理药剂
CN105456517A (zh) * 2015-12-15 2016-04-06 彭国能 一种治疗慢性乙型肝炎的中药组合物、制剂及制备方法
CN107496476A (zh) * 2017-09-29 2017-12-22 北京健旭康技术有限公司 白云花的益肝作用及应用技术
CN109364074B (zh) * 2018-11-01 2021-05-07 重庆医科大学 6-氨基烟酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
WO2020118159A1 (en) * 2018-12-07 2020-06-11 The University Of Chicago Methods and compositions comprising an nfkb inhibitor and an adjuvant
CN113069445A (zh) * 2021-05-11 2021-07-06 重庆医科大学 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途
CN113304165B (zh) * 2021-07-15 2022-07-22 重庆医科大学 单体化合物Ciliatoside A在制备乙型肝炎治疗药物中的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069445A (zh) * 2021-05-11 2021-07-06 重庆医科大学 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途

Also Published As

Publication number Publication date
WO2022237007A1 (zh) 2022-11-17
CN113069445A (zh) 2021-07-06

Similar Documents

Publication Publication Date Title
Liu et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA
AU2021107213A4 (en) Use of sphondin as an effective component in preparing medicine for treating hepatitis b
JP2012522013A (ja) 調節ｉｒｅｓ媒介翻訳
Huang et al. Antiviral activity of chemical compound isolated from Artemisia morrisonensis against hepatitis B virus in vitro
CN107635566A (zh) 治疗hbv感染的组合物和方法
CN112675174B (zh) 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途
CN108929870B (zh) 抑制HBV的siRNA分子及其应用
Li et al. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative
US8580759B2 (en) Anti-hepatitis C virus composition
WO2018193902A1 (ja) マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果
Wen et al. Flavonoids derived from licorice suppress LPS-induced acute lung injury in mice by inhibiting the cGAS-STING signaling pathway
US10123997B2 (en) Target for treating hepatitis B virus
JPH05507481A (ja) ウイルス性肝炎の診断及び治療
Michelet et al. Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro
EP3395363B1 (en) Compounds for use in treating hbv-and hcv-related conditions
CN116327943A (zh) Klf15在酒精性肝病中的应用
CN114796233A (zh) 积雪草酸在制备乙型肝炎治疗药物中的用途
JP2023510274A (ja) Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用
CN109771410B (zh) 紫草酸在制备抗乙肝病毒药物中的用途
EP3773575A1 (en) Methods for treating hepatitis b virus (hbv) infection
Dong et al. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma
JP2020513232A (ja) 糖代謝異常の検出方法と予防及び治療
CN117159529B (zh) 棕榈酰化抑制剂及棕榈酰化酶zdhhc24抑制剂在肝癌中的应用
CN111172165B (zh) siRNA和透膜肽联合治疗肝癌的用途
CN113908278B (zh) miR-221及其抑制剂用于制备调控肝脂肪沉积、肝纤维化或肝细胞癌的药物

Legal Events

Date Code Title Description
FGI Letters patent sealed or granted (innovation patent)